Introduction
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Read more about CiMaas Immunotherapy products,
or watch our video.
After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas as of December 18, 2022.
CiMaas BV, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary NK cell expansion platform, announced the date for a presentation of the company at the Biotech Showcase 2023, the investor conference as follows: Monday, January 09, 2023, at 3:00PM at the Hilton San Francisco - Union Square, 333 O'Farrell Street, Ballroom Level San Francisco, CA 94102, USA.
CiMaas successfully expands Natural Killer (NK) cells to clinically relevant numbers using a 2-week protocol. Starting from 200 ml peripheral blood, NK are expanded to numbers meeting the expected clinically required 10.E8 cells/kg, with multiple infusions. This makes the expansion method developed directly applicable for clinical application of the produced NK cells in anti-cancer therapies.